Pneumrx, Inc. Announces Ce Mark Approval For Its Repneu(r) Lung Volume Reduction Coil (lvrc(tm)) Sys

< BACK TO COMPANY starstarstarstarstar   Business - Company Press Release
14th October 2010, 09:03am - Views: 775





Business Company PneumRx, Inc. 1 image

Business Company PneumRx, Inc. 2 image







MEDIA RELEASE PR41730

 


PneumRx, Inc. Announces CE Mark Approval for Its RePneu(R) Lung Volume Reduction Coil

(LVRC(TM)) System


MOUNTAIN VIEW, Calif., Oct. 14 /PRNewswire-AsiaNet/ --



    PneumRx, Inc. (www.pneumrx.com), a medical device company dedicated to

bringing innovation and improvements to the treatment of lung disease, today

announced that it has received CE Mark approval for its RePneu Lung Volume

Reduction Coil (LVRC) System to treat the later stages of emphysema.


    The RePneu LVRC System is a minimally invasive device intended to improve

lung function in emphysema patients by brochoscopically implanting Nitinol

coils into the lungs to compress damaged tissue (lung volume reduction) and

restore elastic recoil to the healthier lung tissue. This treatment offers a

minimally invasive alternative to lung volume reduction surgery, and works

independently of collateral ventilation.


    The CE mark approval enables PneumRx to move forward with

commercialization in Europe and other select markets. PneumRx intends to

launch its RePneu LVRC System in Europe in the last quarter of 2010. PneumRx

plans to continue its ongoing partnership with physicians through training

and by offering novel products for the diagnosis and treatment of lung

disease.


    "We are thrilled to have achieved this important milestone, and look

forward to introducing our RePneu LVRC to the European market to help improve

the lives of so many people who are suffering from emphysema and have few

other viable treatment options," said Erin McGurk, President and CEO of

PneumRx, Inc. "We are extremely pleased with the significant improvements in

pulmonary function tests, exercise tolerance, and quality of life experienced

by our clinical trial patients, and expect to bring these same benefits to a

broader population of emphysema patients with the commercialization of the

RePneu LVRC System in Europe."


    About PneumRx, Inc.

    PneumRx, Inc. is a rapidly growing medical device company focused on the

development and commercialization of innovative products to treat emphysema

using minimally-invasive techniques. It is a privately held company located

in Mountain View, California.


     SOURCE: PneumRx, Inc.


    CONTACT: PneumRx, Inc.

             +1-650-625-8910









AsiaNet releases please visit http://www.asianetnews.net







news articles logo NEWS ARTICLES
Contact News Articles |Remove this article